Crispr Therapeutics shares tumble after significant earnings miss
BRENTWOOD, Tenn.—Soreq Avigal, the President and CEO of Delek US Holdings, Inc. (NYSE:DK), recently acquired shares in the company, according to a Form 4 filing with the Securities and Exchange Commission. On March 10, Avigal purchased 715 shares of Delek US Holdings’ common stock at an average price of $13.95 per share. This transaction amounted to a total investment of $9,974. The purchase comes as the stock trades near its 52-week low of $13.41, having declined about 14% in the past week. According to InvestingPro, the stock’s RSI suggests oversold conditions.
Following this acquisition, Avigal’s total direct ownership in the company stands at 182,789 shares. Delek US Holdings, headquartered in Brentwood, Tennessee, is engaged in petroleum refining and related services. With a market capitalization of $846 million, the company offers a notable 7.54% dividend yield. InvestingPro analysis reveals 12 additional key insights about the company’s financial health and market position, available in the comprehensive Pro Research Report.
In other recent news, Delek US Holdings, Inc. reported a larger-than-expected loss for Q4 2024, with earnings per share at -$2.54, compared to the forecasted -$1.89. The company’s revenue also fell short, coming in at $2.37 billion against an expected $2.64 billion. Delek reported a net loss of $414 million for the quarter, highlighting a challenging financial environment. Despite these setbacks, the company is focusing on operational improvements and strategic initiatives, such as the Enterprise Optimization Plan, which aims to enhance cash flow. In a separate development, Raymond (NSE:RYMD) James analyst Justin Jenkins revised Delek’s price target to $24 from $25, while maintaining an Outperform rating, noting the company’s strategic measures to navigate a challenging macroeconomic landscape. Jenkins expressed confidence in Delek’s ongoing efforts, including retail sales, midstream acquisitions, and contract extensions, as part of their sum-of-the-parts strategy. Looking ahead, Delek has set a 2025 capital outlook of $150 million to $170 million and expects no major turnarounds for the year. The company is optimistic about its Enterprise Optimization Plan, which aims to improve cash flow by $80 million to $120 million annually starting in the latter half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.